Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 20 | 2023 | 968 | 1.570 |
Why?
|
| Health Care Costs | 10 | 2019 | 700 | 1.030 |
Why?
|
| Quality-Adjusted Life Years | 16 | 2021 | 235 | 0.970 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2021 | 64 | 0.890 |
Why?
|
| Rhytidoplasty | 1 | 2022 | 14 | 0.820 |
Why?
|
| Drugs, Generic | 1 | 2021 | 36 | 0.780 |
Why?
|
| Drug Costs | 1 | 2021 | 140 | 0.710 |
Why?
|
| Decision Support Techniques | 5 | 2019 | 605 | 0.690 |
Why?
|
| Wound Healing | 4 | 2019 | 760 | 0.650 |
Why?
|
| Scleroderma, Localized | 1 | 2018 | 13 | 0.640 |
Why?
|
| Raynaud Disease | 1 | 2018 | 12 | 0.640 |
Why?
|
| Skin Ulcer | 1 | 2018 | 72 | 0.620 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 33 | 0.570 |
Why?
|
| Primary Prevention | 1 | 2017 | 243 | 0.510 |
Why?
|
| Prescription Drugs | 1 | 2015 | 63 | 0.490 |
Why?
|
| Insurance Coverage | 4 | 2023 | 274 | 0.450 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 481 | 0.440 |
Why?
|
| Forehead | 2 | 2022 | 26 | 0.420 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 878 | 0.410 |
Why?
|
| Models, Economic | 5 | 2019 | 102 | 0.360 |
Why?
|
| Replantation | 2 | 2019 | 58 | 0.320 |
Why?
|
| Fingers | 2 | 2019 | 129 | 0.310 |
Why?
|
| Education, Medical, Continuing | 2 | 2017 | 234 | 0.250 |
Why?
|
| Sex Reassignment Surgery | 1 | 2023 | 14 | 0.230 |
Why?
|
| Insurance, Health | 2 | 2023 | 263 | 0.220 |
Why?
|
| United States | 15 | 2023 | 16066 | 0.220 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 1060 | 0.220 |
Why?
|
| Rhinoplasty | 1 | 2023 | 54 | 0.210 |
Why?
|
| Eyebrows | 1 | 2022 | 18 | 0.210 |
Why?
|
| Amputation, Traumatic | 2 | 2019 | 13 | 0.210 |
Why?
|
| Tissue Expansion | 1 | 2022 | 71 | 0.210 |
Why?
|
| Rejuvenation | 1 | 2022 | 23 | 0.210 |
Why?
|
| Finger Injuries | 2 | 2019 | 20 | 0.200 |
Why?
|
| Medicare | 4 | 2016 | 935 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5566 | 0.200 |
Why?
|
| Ear, External | 1 | 2021 | 44 | 0.190 |
Why?
|
| Cicatrix | 1 | 2022 | 188 | 0.190 |
Why?
|
| Vascular Grafting | 2 | 2019 | 47 | 0.190 |
Why?
|
| Arteries | 2 | 2019 | 294 | 0.180 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 13 | 0.180 |
Why?
|
| Orphan Drug Production | 1 | 2020 | 9 | 0.180 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 18 | 0.180 |
Why?
|
| Humans | 35 | 2023 | 272087 | 0.180 |
Why?
|
| Research Design | 2 | 2018 | 1581 | 0.170 |
Why?
|
| Skin | 2 | 2022 | 1284 | 0.170 |
Why?
|
| Leeching | 1 | 2019 | 3 | 0.170 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 81 | 0.160 |
Why?
|
| Surgery, Plastic | 1 | 2021 | 149 | 0.160 |
Why?
|
| Endoscopy | 1 | 2022 | 501 | 0.160 |
Why?
|
| Gross Domestic Product | 1 | 2018 | 2 | 0.160 |
Why?
|
| Graft Survival | 2 | 2019 | 1092 | 0.160 |
Why?
|
| Dermatologic Agents | 1 | 2018 | 44 | 0.160 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 291 | 0.150 |
Why?
|
| Life Tables | 1 | 2018 | 122 | 0.150 |
Why?
|
| Upper Extremity | 1 | 2018 | 83 | 0.150 |
Why?
|
| Triterpenes | 1 | 2018 | 68 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2018 | 106 | 0.150 |
Why?
|
| Clinical Competence | 2 | 2016 | 1327 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 16612 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2019 | 6885 | 0.150 |
Why?
|
| Prognosis | 4 | 2019 | 22555 | 0.140 |
Why?
|
| Perforator Flap | 1 | 2019 | 96 | 0.140 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 23 | 0.140 |
Why?
|
| Income | 1 | 2018 | 232 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 12012 | 0.140 |
Why?
|
| Surgical Flaps | 1 | 2022 | 882 | 0.140 |
Why?
|
| Educational Measurement | 2 | 2016 | 398 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2018 | 238 | 0.130 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 257 | 0.130 |
Why?
|
| Certification | 1 | 2016 | 109 | 0.130 |
Why?
|
| Developing Countries | 1 | 2018 | 340 | 0.130 |
Why?
|
| Regeneration | 1 | 2018 | 287 | 0.120 |
Why?
|
| Decision Making | 3 | 2017 | 1247 | 0.120 |
Why?
|
| Choice Behavior | 2 | 2014 | 206 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 847 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 472 | 0.120 |
Why?
|
| Health Policy | 2 | 2014 | 281 | 0.120 |
Why?
|
| Ischemia | 2 | 2019 | 408 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2021 | 1349 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 226 | 0.110 |
Why?
|
| Multiple Myeloma | 2 | 2015 | 2287 | 0.110 |
Why?
|
| Anesthesiology | 1 | 2015 | 146 | 0.110 |
Why?
|
| Nerve Block | 1 | 2015 | 185 | 0.110 |
Why?
|
| Male | 14 | 2023 | 129088 | 0.110 |
Why?
|
| Sympathectomy | 1 | 2012 | 16 | 0.110 |
Why?
|
| Efficiency | 1 | 2013 | 94 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 692 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2013 | 79 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2021 | 33909 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 2015 | 418 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2013 | 201 | 0.100 |
Why?
|
| Perception | 1 | 2013 | 351 | 0.090 |
Why?
|
| Patients | 1 | 2013 | 248 | 0.090 |
Why?
|
| Female | 13 | 2021 | 149288 | 0.090 |
Why?
|
| Lower Extremity | 1 | 2012 | 284 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 9046 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 700 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 1076 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 813 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 12534 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4400 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2400 | 0.070 |
Why?
|
| Hospitalization | 1 | 2017 | 2203 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2014 | 931 | 0.070 |
Why?
|
| SEER Program | 3 | 2016 | 1047 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 6987 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 616 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 962 | 0.070 |
Why?
|
| Child | 3 | 2022 | 30559 | 0.070 |
Why?
|
| Heart Failure | 1 | 2020 | 2500 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 5935 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1232 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 4352 | 0.060 |
Why?
|
| Logistic Models | 3 | 2019 | 3469 | 0.060 |
Why?
|
| Registries | 3 | 2018 | 2253 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15279 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 2634 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 2266 | 0.060 |
Why?
|
| Gender Identity | 1 | 2023 | 79 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1950 | 0.050 |
Why?
|
| Hypertension | 1 | 2012 | 1624 | 0.050 |
Why?
|
| Nose | 1 | 2023 | 140 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2019 | 39831 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2021 | 918 | 0.050 |
Why?
|
| Markov Chains | 2 | 2012 | 184 | 0.050 |
Why?
|
| Aged | 9 | 2020 | 73517 | 0.050 |
Why?
|
| Face | 1 | 2023 | 251 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 6270 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2021 | 145 | 0.050 |
Why?
|
| Esthetics | 1 | 2021 | 116 | 0.050 |
Why?
|
| Middle Aged | 5 | 2019 | 90460 | 0.050 |
Why?
|
| Epoetin Alfa | 1 | 2020 | 27 | 0.050 |
Why?
|
| Quality of Life | 1 | 2015 | 4755 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2017 | 1572 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2021 | 422 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 196 | 0.040 |
Why?
|
| Suture Techniques | 1 | 2021 | 292 | 0.040 |
Why?
|
| Degloving Injuries | 1 | 2019 | 2 | 0.040 |
Why?
|
| Crush Injuries | 1 | 2019 | 5 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2021 | 550 | 0.040 |
Why?
|
| Hyperemia | 1 | 2019 | 37 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 313 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 13139 | 0.040 |
Why?
|
| Comorbidity | 2 | 2015 | 2439 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 166 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 29 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 48 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2019 | 294 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 144 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 258 | 0.040 |
Why?
|
| Streptokinase | 1 | 2017 | 24 | 0.040 |
Why?
|
| American Medical Association | 1 | 2016 | 14 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2016 | 40 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2018 | 243 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 718 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2014 | 9500 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 5118 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 161 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2016 | 130 | 0.030 |
Why?
|
| Age Factors | 2 | 2015 | 5526 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 14653 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2019 | 1433 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 583 | 0.030 |
Why?
|
| Decision Making, Organizational | 1 | 2015 | 8 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 51 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 14 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 31066 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2017 | 251 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 442 | 0.030 |
Why?
|
| Comprehension | 1 | 2015 | 104 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 303 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2019 | 865 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 393 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 505 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 153 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6210 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2021 | 17056 | 0.030 |
Why?
|
| Video Recording | 1 | 2015 | 283 | 0.030 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2014 | 109 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2014 | 316 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 776 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 2015 | 0.020 |
Why?
|
| Learning | 1 | 2015 | 433 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2018 | 1159 | 0.020 |
Why?
|
| Psychometrics | 1 | 2015 | 964 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 2048 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2335 | 0.020 |
Why?
|
| Catheterization | 1 | 2012 | 425 | 0.020 |
Why?
|
| Adult | 4 | 2019 | 81933 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4371 | 0.020 |
Why?
|
| Patient Participation | 1 | 2013 | 452 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1264 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 691 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 2681 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 1304 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 1950 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 738 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2290 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 4496 | 0.020 |
Why?
|
| Communication | 1 | 2013 | 858 | 0.020 |
Why?
|
| Neoplasms | 1 | 2013 | 15930 | 0.020 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 473 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 2430 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2015 | 1441 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 4138 | 0.010 |
Why?
|
| Animals | 2 | 2019 | 62822 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 13970 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 3925 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 22142 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2307 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 32730 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 36053 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 18051 | 0.010 |
Why?
|